2.55Open2.55Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover259.65%IV2.39%PremiumOct 18, 2024Expiry Date2.49Intrinsic Value100Multiplier18DDays to Expiry0.06Extrinsic Value100Contract SizeAmericanOptions Type-0.8114Delta0.1863Gamma0.97Leverage Ratio-0.0102Theta-0.0018Rho-0.78Eff Leverage0.0015Vega
Nextdoor Holdings Stock Discussion
In reaction to earnings/guidance:
• $Wolfspeed (WOLF.US)$ +22.2%, $Canadian Solar (CSIQ.US)$ +6.5%, $BJ's Wholesale Club Holdings (BJ.US)$ +5.8%, $Cisco (CSCO.US)$ +5.3%, $Keysight Technologies (KEYS.US)$ +4.3%, $Madison Square Garden Sports (MSGS.US)$ +3%, $NetEase (NTES.US)$ +2.7%, $NICE Ltd (NICE.US)$ +2.1%, $Synopsys (SNPS.US)$ + 1.8%
News:
• $Brooge Energy (BROG.US)$ +17.1% (says majority shareholder, BPGIC Holdings, would like to take ...
In reaction to earnings/guidance:
• $The Trade Desk (TTD.US)$+17%, $Workiva (WK.US)$ +15.3%, $Arlo Technologies (ARLO.US)$ +12%, $Array Technologies (ARRY.US)$ +10.3%, $Everbridge (EVBG.US)$ +9.7%, $Catalyst Pharmaceuticals (CPRX.US)$ +9.4%, $Halozyme Therapeutics (HALO.US)$ +8.7%, $Velo3D (VLD.US)$ +7.6%, $CyberArk (CYBR.US)$ + 6.2%, $Haemonetics (HAE.US)$ +5.8%, $Jackson Financial (JXN.US)$ +5.7% (also increases dividend), $Axon Enterprise (AXON.US)$ +4.8%, ...
• $Repare Therapeutics (RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy (CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath (PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage (PSTG.US)$ +10.6% (In reaction to earnings)
• $Credo Technology (CRDO.US)$ +10.2% (In reaction ...
Which businesses and corporate leaders are shaping our future? That's the question at the heart of TIME100 Most Influential Companies, an annual list that highlights businesses making an extraordinary impact around the world.
To assemble it, TIME solicits nominations across sectors including health care, entertainment, technology, and more from our...
No comment yet